Compass Therapeutics (CMPX) Corporate presentation summary

Corporate highlights and financial position

• Achieved primary endpoint in Phase 2/3 study for tovecimig in second-line biliary tract cancer (BTC), with key secondary endpoints expected in April 2026.

• 17.1% overall response rate (ORR) in 2L BTC patients, compared to 5% with FOLFOX.

• Multi-billion dollar market potential in BTC, with over $1B opportunity in the US and 85% of 2L BTC patients lacking approved alternatives.

• Four novel clinical antibody candidates in the pipeline.

• Cash runway into 2028 with $209M projected at year-end 2025.

Pipeline and clinical development

• Robust pipeline includes tovecimig (DLL4 x VEGF-A), CTX-471 (CD137 agonist), CTX-8371 (PD-1 x PD-L1 bispecific), and CTX-10726 (PD-1 x VEGF-A bispecific).

• Tovecimig demonstrated monotherapy and combination activity in multiple tumor types, with ongoing and planned studies in BTC, CRC, gastric, ovarian, renal, and HCC.

• CTX-471 showed responses in melanoma, mesothelioma, and small cell lung cancer, with NCAM (CD56) as a potential biomarker.

• CTX-8371 and CTX-10726 are advancing through early clinical and preclinical development, showing promising anti-tumor activity.

Tovecimig clinical data and market opportunity

• Phase 2/3 COMPANION-002 study in 2L BTC showed 17.1% ORR for tovecimig + paclitaxel vs. 5.3% for paclitaxel alone (p=0.031).

• Safety profile consistent with prior studies; independent monitoring recommended continuation without modification.

• PFS and OS data expected in April 2026; >20% OS at >18 months median follow-up as of September 2025.

• US BTC incidence projected to grow to ~34,000 by 2037, with significant unmet need in 2L setting.

• Tovecimig granted Fast Track Designation in BTC in April 2024.